Objectives: To evaluate cases of chronic Chagas' disease for the long-term effects of treatment with itraconazole on Trypanosoma cruzi infections and the regression or development of ECG abnormalities.
Introduction
American trypanosomiasis is a neglected tropical disease caused by Trypanosoma cruzi, which is endemic from Patagonia to the northern border of Mexico. 1 An important flow of migration from Latin America to the northern countries at the beginning of the 21st century caused the emergence of imported cases in non-endemic countries such as the USA, Australia, Europe and Japan. It is estimated that there are 350 000 cases in the USA and 100 000 cases in Europe, 87 000 of which are in Spain. 2 There are 8 -10 million individuals infected with T. cruzi in Latin America, more than half of whom are in the Southern Cone. Uruguay, Chile, Brazil, Paraguay, part of Argentina, Peru and Bolivia have been declared free of transmission by Triatoma infestans, the main vector of the disease. 3 In Chile, 150000 persons are infected with T. cruzi; 30% of them will develop some degree of cardiopathy and one in three will probably require a pacemaker to survive. 4, 5 At present, there is a consensus that all the individuals who are infected with T. cruzi should be treated unless they have reached the late chronic phase of the infection or have developed decompensated chronic heart failure. 6 No drug approved for clinical use currently provides entirely satisfactory treatment for chronic T. cruzi infection although there are many drugs with activity against T. cruzi; the only ones that can currently be given to humans on the basis of ethical and clinical considerations are nifurtimox and benznidazole. Unfortunately, the use of these drugs has been limited by their restricted availability and the significant adverse effects that they sometimes cause in adults. purpose, two antimycotics-posaconazole (Merck Sharp & Dohme) 11 and ravuconazole (Bristol Myers Squibb), 12 drugs with good efficacy against T. cruzi-have been applied to chronic chagasic patients (in Phase II protocols). Itraconazole, a synthetic imidazole derivative similar to posaconazole, 13, 14 has shown good efficacy against T. cruzi both in vitro and in vivo, resulting for example in the total cure of chronically infected mice. 15, 16 This drug has been used as an efficient antimycotic in humans for the last 32 years without causing important side effects. The aim of this study was to evaluate, among cases of chronic Chagas' disease, the long-term effects of treatment with itraconazole on T. cruzi infections and the regression or development of ECG abnormalities.
Methods

Patients
The present study represented a 20 year follow-up of patients treated with itraconazole 6 mg/kg/day for 120 days in a blind evaluation of the efficacy of the drug in the treatment of chronic American trypanosomiasis. 17 This investigation was accepted by the Ethics Committee of the Faculty of Medicine of the University of Chile and informed consent was given by all patients (Project Fondecyt 092/0920). A total of 46 patients were checked for ECG abnormalities and microscopic or molecular evidence of current T. cruzi infections. Each patient was subjected to a 12-lead ECG examination before treatment, after 4, 8 and 12 months and once a year for 19 years, following the blind protocol recommended by the WHO. 4, 18 The investigator analysing the ECG traces was unaware of each patient's infection status in the previous follow-up and/or for any follow-up.
In the formal analysis, the results of the ECG examinations from the 20 year follow-up were compared with the corresponding results recorded earlier. This allowed each patient to be categorized as: normal/normal (indicating prevention of cardiopathy), these cases having a normal ECG at baseline and during the yearly check-ups until the 20 year follow-up; abnormal/normal (indicating regression of the cardiopathy), these patients having an abnormal ECG at baseline and during the first check-ups, but a normal ECG in the final 5 years; normal/abnormal (indicating conversion), these cases having a normal ECG at baseline, during the serial follow-up and in the last 5 years developed an abnormal ECG; and abnormal/abnormal (indicating maintenance of the cardiopathy), these patients having a abnormal ECG at baseline and during the yearly check-ups until the 20 year follow-up. 19, 20 The abnormal ECG traces were classified as major and minor. Major abnormalities were conduction alterations such as second-and third-degree atrioventricular block or intraventricular blocks, ischaemia on imaging and a prolonged QTc interval. Minor abnormalities were rhythm alterations such as auricular tachycardia, extrasystoles, auricular parasystoles, ventricular parasystoles and short runs of ventricular tachycardia.
Control group
Sixty-seven patients with chronic Chagas' disease of indeterminate duration were followed for 4 years; these patients constituted the historical control group (1981-84). For ethical reasons, this group was treated after the experimental period.
Parasitology
Every 12 months for 20 years, a 2 mL sample of venous blood was collected from each patient, and in a xenodiagnosis (XD) method uninfected T. infestans were allowed to feed on the patients. Both procedures were performed simultaneously. 21 PCR assays were then used to check the blood sample, and XD-quantitative PCR (XD-qPCR) was applied to faecal samples (FS) to check for T. cruzi DNA in a random sample of XD applied to 16 patients. Each test was duplicated. All the FS of T. infestans were also studied under the microscope as wet smears for flagellates. A patient was positive if he or she was considered to be infected with T. cruzi on any of these tests.
Xenodiagnosis
Seven third-or fourth-instar nymphs of T. infestans that were free of infection and held in a mesh-topped wooden box were fed on a patient and then maintained at 278C and 80% humidity. Microscopic examination of the FS was performed 30, 60 and 90 days after feeding the triatomines. For XD-qPCR, the FS of all the triatomines obtained after each period of incubation were mixed with 500 mL of PBS buffer at pH 7.2, incubated at 988C for 15 min and then centrifuged at 4000 g for 3 min. The supernatants were stored at 2208C until the DNA was extracted for use. 21 
DNA extraction from blood
A subsample (2 mL) of each patient's blood was mixed with the same volume of a 6 M guanidine hydrochloride/0.2 M EDTA solution, incubated at 988C for 15 min to break the minicircles of T. cruzi kinetoplasts and stored at 48C. DNA extraction was performed on 200 mL of guanidinemixed samples, using the FavorPrep Blood Genomic DNA Extraction Kit (Favorgen Biotech Corp) according to the manufacturer's instructions, and maintained at 2208C until use. 21 
PCR of blood
The PCR assay used to investigate the blood DNA samples was performed in triplicate with oligonucleotides 121 and 122, which anneal to the four constant regions present in minicircles of T. cruzi, to obtain 320 bp amplicons. 22 PCR was performed in a final volume of 20 mL containing 2.5 mM MgCl 2 , 0.2 mM of each dNTP, 0.5 mM of each primer (121 and 122) and 1 unit of GoTaq DNA polymerase (Promega Corp). The amplification programme was performed in a TC-412 thermal cycler (Techne), and included an initial denaturation at 988C for 1 min and 648C for 2 min, 33 cycles of 948C for 1 min, 648C for 1 min and 728C for 1 min, and a final elongation at 728C for 10 min. Each experiment included 5 mL of BenchTop 100 bp DNA ladder (Promega Corp), a PCR control that contained water instead of DNA, DNA from non-chagasic patients and as a positive control the purified DNA-T. cruzi Tulahuén strain. Amplification products were analysed by electrophoresis in a 2% agarose gel and visualized by staining with GelRed (Biotium). 21 The analytical sensitivity was determined by qPCR of blood using 50 chronic chagasic cases with demonstrated parasitaemia by XD and PCR in the blood. The lower limit of detection was 0.1 parasites/mL (I. Zulantay, E. Araya, M. Saavedra, W. Apt, G. Martínez, unpublished results).
DNA extraction from FS
Before the FS-DNA isolation process, 20 ng equivalent of negative human blood DNA was added as an exogenous internal control. 23 DNA purification was performed using a 100 mL initial volume with the FavorPrep Blood Genomic DNA Extraction Mini Kit (Favorgen, Biotech Corp.), modified by omitting the step of cell lysis with proteinase K. The elution process was similar to that described for human blood. Samples were maintained at 2208C until XD-qPCR was carried out. All the calculations were made assuming that T. cruzi genetic material has a mass of 200 fg. 24 In parallel, as an internal exogenous control, human chromosome 12 (X12) was used, adding a quantity equivalent to 20 ng of human genomic DNA free of the disease to each of the FS before the extraction process. The exogenous internal control was designed, first, to discard false-negative cases caused by the absence of DNA in the evaluated sample due to extraction problems, and second, to assess whether there was inhibition in the PCR reaction. The primers N1X12 forward (5 ′ -AGCTGGCTAGACTGTCAT-3 ′ ) and N2X12 reverse (5 ′ CTTTGCCGTTGAAGCTTG-3 ′ ) and the probe N3X12 (not published) were used. The reaction mixture was composed of 2 mL of the sample to be investigated, 10 mL of Brilliant Multiplex QPCR Master Mix, 0.5 mL of a 1: 500 solution of ROX, 2 mL of N3X12, 0.2 mL of BSA (100×) and 2.5 mL of molecular biology grade water, in a final reaction volume of 20 mL. To produce a standard curve, a 1 :5 dilution of human genomic DNA was used with a known amount of X12, utilizing six known points to quantify the sample. 21 Both reactions were performed in the same assay with three respective controls, using the same thermal profile, which consisted of 10 min of pre-incubation at 958C and 40 cycles of amplification. The emitted fluorescence recording was performed at 608C at the end of each cycle. Results were analysed with the software MxPro X4.1 (Agilent Technologies).
XD-qPCR
Statistics
The sensitivities of each parasitological test were compared and the relationship between the infection status and ECG developments observed were explored statistically using the x 2 test, Fisher's exact test, McNemar test and percentage differences, considering P values ,0.05 as significant.
Results
By comparing the pre-treatment ECG with those performed during the 20 follow-up years, the 46 patients investigated in this study were categorized as normal/normal, abnormal/normal, normal/ abnormal or abnormal/abnormal. These groups were similar in mean age and in the prevalence of infection, as indicated by positivity of any one of the parasitological tests 20 years posttreatment. Twenty-one (45.6%) of the 46 patients studied were infected. Of the patients with a normal ECG at baseline who maintained the ECG tracing at 20 years, 34.7% were infected. No statistical differences were observed between the ECG results and the infection. One case with an abnormal pre-treatment ECG tracing, left anterior hemiblock and incomplete right bundle branch block had normal traces after 20 years of follow-up. Five patients with a normal pre-treatment ECG had abnormal traces at least 20 years after treatment; two had a prolonged QTc interval, one had a prolonged QTc and sinus bradycardia, one had sinus bradycardia and one had left hypertrophy (Table 1) .
Only 10 patients were positive for T. cruzi by XD (21.7%), but 21 had a positive PCR for a blood sample (45.7%). XD was significantly less likely to give a positive result for a patient than was the PCR-based assay of a blood sample from the sample patient. Positive XD had the same results with PCR, nevertheless, 30.5% of the negative XD had positive PCR (McNemar test P,0.001; Table 2 ).
Most of the patients with major ECG abnormalities maintained the alterations after 20 years (Table 3 ). The patients with minor abnormalities (for example extrasystoles and parasystoles) showed an improvement in these alterations 20 years after treatment (Table 3) .
The XD-qPCR performed on 16 treated patients demonstrated very low parasite loads. Ten had ,1.42 parasites/mL, eight of Apt et al.
them with ,1 parasite/mL, one with 1.42 parasite/mL and one with 1.01 parasites/mL. In one case, the patient's XD sample did not show amplification. Only five cases had more than 11.75 parasites/mL, all of which had a positive XD (Table 4) .
Discussion
The patients categorized as normal/abnormal in the last or earlier follow-ups were initially chosen as part of the infected historical control group. By 20 years post-treatment, however, 10.9% of those who had had a normal ECG pre-treatment had developed detectable ECG abnormalities, most of which were minor ECG alterations. Those found to have developed ECG alterations between the initiation of treatment and the 20 year follow-up still had abnormal ECG traces almost two decades later ( Table 3 ). The one patient with an abnormal ECG at baseline who showed normal ECG traces after treatment and follow-up indicates that itraconazole can cure some T. cruzi-related cardiopathy (Table 1) . Of the patients who had normal ECG traces at baseline-28 of 46 (60.8%)-only five showed evidence of ECG abnormalities during the 20 years of follow-up, which represents an annual rate of 0.5%; this indicates that the itraconazole they received stopped, or at least slowed, the natural evolution of their trypanosomiasis (Tables 1 and 2 ) since in a historical control group with Chagas' disease in Chile followed for 4 years, we demonstrated that 9.7% per year of the patients with a normal ECG (indeterminate period) developed abnormalities in their ECG traces. 4 This lower annual rate of ECG abnormalities was statistically significant (Z¼ 2.03, P ¼0.0212).
During the 20 years of follow-up, no mortality attributable to T. cruzi infection was observed in the treated patients. This is encouraging and could indicate some effect of the treatment, since there is a 1.85% annual risk of death among patients with Chagas cardiopathy who are left untreated. 4 The results of XD-qPCR, performed in 16 patients, confirm the effect of itraconazole on T. cruzi load after 20 years of treatment, since 10 of the cases had a parasite load between ,1 (eight cases) to 1.42 parasites/mL (one 1.01 and the other 1.42). In one case, no amplification of the XD sample could be obtained. In five cases, the parasite load detected was between 11.75 and 422.7 parasites/mL; all these cases had a positive XD. The result of these cases clearly demonstrated treatment failure because reinfection is unlikely due to control of T. infestans.
25
The number of parasites quantified by XD-qPCR could be related to the efficiency of replication in the insect and the initial inoculum during feeding. However, this hypothesis must be confirmed by other investigations.
Twenty-five (54.3%) of the patients investigated were negative in all the parasitological tests used, and 15 (60%) of these cases had normal ECG traces at 20 years follow-up. These parasite-negative individuals with a normal ECG should probably be considered 'cured' but all of them still appeared to be seropositive at 20 years follow-up, with titres ranging between 1/20 and 1/160 for indirect immunofluorescence and an optical 26 this could explain the persistent seropositivity of the treated patients of this study in the absence of T. cruzi infection.
The present results indicate that itraconazole is effective in the treatment of chronic American trypanosomiasis in Chile. Most of the circulating strains in the area where Chagas' disease is endemic correspond to TcII, which is sensitive to itraconazole. 27 It is possible that the cases that did not respond to treatment had been infected with strain TcI, which is resistant to this drug. 28 No drug currently used to treat chronic chagasic patients has a high efficacy and low number of secondary effects. Itraconazole is an azole drug that has demonstrated few side effects (one case of hepatic toxicity has been described) 15, 19, 29 in relation to other drugs currently used, such as nifurtimox or benznidazole, 30, 31 and can prevent the development of ECG abnormalities as shown here, and cause the regression of some ECG abnormalities. Posaconazole and ravuconazole, other azoles that belong to the triazole family, have demonstrated high efficiency in in vitro and in vivo experiments. Current international Phase II clinical studies involving these drugs will allow a determination of their efficacy. We hope that there will be in the near future an integrated solution for individuals infected with T. cruzi, who represent an important public health problem.
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